首页>
外国专利>
Predictive Test for Melanoma Patient Benefit from Interleukin-2 (IL2) Therapy
Predictive Test for Melanoma Patient Benefit from Interleukin-2 (IL2) Therapy
展开▼
机译:黑色素瘤患者从白介素2(IL2)治疗中获益的预测测试
展开▼
页面导航
摘要
著录项
相似文献
摘要
A method is disclosed for predicting in advance whether a melanoma patient is likely to benefit from high dose IL2 therapy in treatment of the cancer. The method makes use of mass spectrometry data obtained from a blood-based sample of the patient and a computer configured as a classifier and making use of a reference set of mass spectral data obtained from a development set of blood-based samples from other melanoma patients. A variety of classifiers for making this prediction are disclosed, including a classifier developed from a set of blood-based samples obtained from melanoma patients treated with high dose IL2 as well as melanoma patients treated with an anti-PD-1 immunotherapy drug. The classifiers developed from anti-PD-1 and IL2 patient sample cohorts can also be used in combination to guide treatment of a melanoma patient.
展开▼